Rocket Pharmaceuticals Q2 2025 Earnings Report

Rocket Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.57
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Rocket Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $4.36 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rocket Pharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 8/4/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Rocket Pharmaceuticals (NASDAQ:RCKT), together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.